|
|
|
Medical Informatics Imaging Technology |
| |
CompuMed, Inc. Awarded US Patent for Technology to
Monitor Joint Disease
Other Topics: Health Informatics
Society,
Medical Informatics Equipment
Supplier,
Infection Control Programs,
Radiology Solutions,
Telemedicine and e-Health
CompuMed, Inc.
October 15, 2007
Patent Covers Automated Method and System with Applications
for Osteoarthritis and Rheumatoid Arthritis
Los Angeles -- CompuMed, Inc. (OTCBB:CMPD) – a leading provider
of imaging technology for skeletal health, and the company
behind the OsteoGram™ system for bone density screening – today
announced that the United States Patent and Trademark Office has
issued the company a patent for an automated method and system
to assess or monitor the extent or progression of joint-damaging
diseases such as osteoarthritis and rheumatoid arthritis.
|
| |
|
[ggl-468x60.htm]
|
| |
The
newly awarded patent, titled "Method, Code, and System for
Assaying Joint Deformity," (USPTO # 10/625,444) contains 27
claims that cover CompuMed’s proprietary image processing
technology. This technology includes a new template method that
can be used to detect the extent of joint-damaging disease and
monitor its progress by comparing the patient’s data to a normal
database, as well as the patient’s prior test results.
“We have a vision to extend our core imaging technology beyond
its current markets,” said Xiaoli Bi, M.S., CompuMed’s vice
president, chief technical officer and one of the authors of the
patent. “This Patent protects our ability to extend the range of
applications for our imaging technologies to include Arthritis
disease monitoring.”
CompuMed
CEO Maurizio Vecchione added, “This patent paves the way for new
product strategies and adds to CompuMed’s already significant
patent portfolio of imaging technology. It also makes it
possible for the Company to pursue valuable partnership and
licensing relationships in a wide spectrum of skeletal health
segments.”
About CompuMed
CompuMed, Inc. (OTCBB:CMPD) develops and
markets products and services that combine advanced imaging with
medical informatics. Its focus is on analysis and remote
monitoring for patients with cardiovascular and musculoskeletal
diseases. The Company has specialized expertise and intellectual
property in telemonitoring imaging and analysis designed to
improve healthcare provider workflow and patient care while
reducing costs. CompuMed's core products, the OsteoGram® and
CardioGram(TM), are cleared by the FDA and reimbursable by
Medicare. The OsteoGram is a non-invasive diagnostic system that
has been proven by many clinical studies to provide effective
and accurate bone density measurement for screening osteoporosis
and assessing hip fracture risk. The OsteoGram has significant
cost advantages over other technologies in the marketplace. The
CardioGram system is one of the first telecommunication networks
designed to remotely interpret electrocardiograms and is used by
private practice, as well as government and corporate healthcare
providers nationwide. The CardioGram delivers online
electrocardiogram interpretations within minutes of receipt and
has the additional capability of automatically providing an
over-read (i.e., follow-up review) by a cardiologist. CompuMed
is headquartered in Los Angeles and distributes its products
worldwide both directly and through OEM partners. Visit CompuMed
on-line at www.compumed.net.
Statements contained in this press release that are not
historical facts, such as statements about prospective earnings,
savings, revenue, operations, revenue and earnings growth,
results of contracts and other financial results, are
forward-looking statements pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. All such forward-looking statements including statements
concerning the Company's plans, objectives, expectations and
intentions are based largely on management’s expectations and
are subject to and qualified by risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied by such statements. These statements are
subject to uncertainties and risks including, without
limitation, competitive factors, outsourcing trends in the
pharmaceutical industry, product and service demand and
acceptance, changes in technology, ability to raise capital, the
availability of appropriate acquisition candidates and/or
business partnerships, economic conditions, the impact of
competition and pricing, capacity and supply constraints or
difficulties, government regulation and other risks identified
in the Company's filings with the Securities and Exchange
Commission including its Annual Report on Form 10-KSB and
Quarterly Reports on Form 10-QSB. All such forward-looking
statements are expressly qualified by these cautionary
statements. The Company expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect events, conditions or
circumstances on which any such statement is based after the
date hereof, except as required by law. |
| |
|
|
| |
|
|
